Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 16:23, 16 April 2024

1,653 bytes added ,  16:23, 16 April 2024
Updated
Line 53: Line 53:  
----<br />
 
----<br />
 
|-
 
|-
−
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
+
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
 +
|4/8/24
 +
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 786: Line 788:  
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
−
|PENDING
+
|Tracy Tucker, PhD, FCCMG
−
|
+
|4/6/24
−
|
   
|
 
|
 +
|Pending
 
|
 
|
 
|JH_MS
 
|JH_MS
Line 802: Line 804:  
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
−
|PENDING
+
|Tracy Tucker, PhD, FCCMG
−
|
+
|4/6/24
−
|
   
|
 
|
 +
|Pending
 
|
 
|
 
|JH_MS
 
|JH_MS
Line 1,471: Line 1,473:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING
+
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
 
| || || || ||Shivani Golem (SG)
 
| || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 
|Monoclonal B-cell Lymphocytosis
 
|Monoclonal B-cell Lymphocytosis
 
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
 
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
−
|PENDING
+
|PENDING, 4/30/2024
 
|
 
|
 
|Assigned 12/19/2022 with completion date of 1/19/2023
 
|Assigned 12/19/2022 with completion date of 1/19/2023
Line 1,485: Line 1,487:     
Honey Reddi, PhD, Belay Diagnostics
 
Honey Reddi, PhD, Belay Diagnostics
−
| || ||Complete (Shivani, please confirm)|| ||SG|| ||
+
| || ||Complete|| ||SG|| ||
 
|Already converted to 5th edition
 
|Already converted to 5th edition
 
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
 
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
Line 1,492: Line 1,494:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||PENDING
+
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Hairy Cell Leukemia
 
|Hairy Cell Leukemia
Line 1,500: Line 1,502:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||PENDING
+
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Splenic Marginal Zone Lymphoma
 
|Splenic Marginal Zone Lymphoma
Line 1,508: Line 1,510:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
 
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
Line 1,518: Line 1,520:  
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|Disease
 
|Disease
−
|PENDING
+
|
 
|
 
|
 
|
 
|
Line 1,812: Line 1,814:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
+
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee) + Andrew Siref as mentor
 +
|3/22/24|| ||Pending|| ||GC|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 1,923: Line 1,926:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others")|| || || || ||GC|| ||
+
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 1,953: Line 1,956:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]")|| || || || ||GC|| ||
+
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
 
|
 
|
 
|
 
|
Line 2,085: Line 2,088:  
|
 
|
 
|
 
|
 +
|-
 +
|Disease (5th Edition)
 +
|Page Type
 +
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
 +
|Date Assigned to Author (5th Edition)
 +
|Target Completion Date (5th Edition)
 +
|Content Status (5th Edition) (Pending or Complete)
 +
|Date Completed by Author (5th Edition)
 +
|Associate Editor
 +
|Date of Last Editor Review (5th Edition)
 +
|Notes (5th Edition)
 +
|Correlated Prior Disease Name (4th Edition)
 +
|Correlated Prior Author (4th Edition)
 +
|Prior Content Status (4th Edition) (Pending or Complete)
 +
|Prior Date of Last Editor Review (4th Edition)
 +
|Prior Notes (4th Edition)
 
|-
 
|-
 
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
 
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
Line 2,124: Line 2,143:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
 +
|3/25/2024
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,138: Line 2,159:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||HD|| ||
+
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,147: Line 2,168:  
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
 
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
 
|Disease
 
|Disease
−
|PENDING
+
|Fei Yang, MD
 
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
−
|
+
|SK
−
|HD
   
|
 
|
 
|
 
|
Line 2,163: Line 2,184:  
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
 
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
 
|Disease
 
|Disease
 +
|Parastou Tizro, MD (trainee);
 +
Sumire Kitahara, MD
 +
|3/17/2024
 
|
 
|
−
|
+
|Pending
−
|
  −
|
   
|
 
|
 
|SK
 
|SK
Line 2,177: Line 2,199:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||PENDING
+
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
−
| || || || ||SK|| ||
+
|3/17/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 
|T-cell Large Granular Lymphocytic Leukemia
 
|T-cell Large Granular Lymphocytic Leukemia
 
|Michelle Don, MD, MS
 
|Michelle Don, MD, MS
Line 2,185: Line 2,210:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||PENDING
+
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
−
| || || || ||SK|| ||
+
Michelle Don, MD, MS
 +
|3/17/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 
|Chronic Lymphoproliferative Disorder of NK Cells
 
|Chronic Lymphoproliferative Disorder of NK Cells
 
|Michelle Don, MD
 
|Michelle Don, MD
Line 2,193: Line 2,222:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||PENDING
+
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Adult T-cell Leukemia/Lymphoma
 
|Adult T-cell Leukemia/Lymphoma
Line 2,201: Line 2,230:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||PENDING
+
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
−
| || || || ||SK|| ||
+
|3/22/2024
 +
| || || ||SK|| ||
 
|Sézary Syndrome
 
|Sézary Syndrome
 
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
 
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,217: Line 2,247:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc
 +
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,224: Line 2,257:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
 +
 
 +
Andrew Siref, MD
 +
|4/12/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,231: Line 2,269:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||PENDING
+
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
−
| || || || ||SK|| ||
+
|3/22/2024
 +
| || || ||SK|| ||
 
|Mycosis Fungoides
 
|Mycosis Fungoides
 
|Jane Scribner, MD and Daynna J. Wolff, PhD
 
|Jane Scribner, MD and Daynna J. Wolff, PhD
Line 2,254: Line 2,293:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
 +
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,261: Line 2,303:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
 +
| || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,268: Line 2,311:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
 +
 
 +
Andrew Siref, MD
 +
|4/12/2024|| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,282: Line 2,329:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||PENDING
+
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
 
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Line 2,297: Line 2,344:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
−
| || || || ||SK|| ||
+
Andrew Siref, MD
 +
|3/20/2024
 +
| ||Pending|| ||SK|| ||
 
|Enteropathy-Associated T-cell Lymphoma
 
|Enteropathy-Associated T-cell Lymphoma
 
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
 
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
Line 2,305: Line 2,354:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),
−
| || || || ||SK|| ||
+
Andrew Siref, MD
 +
|3/20/2024
 +
| ||Pending|| ||SK|| ||
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
 
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
Line 2,313: Line 2,364:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||PENDING
+
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
 
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
Line 2,321: Line 2,372:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
−
| || || || ||SK|| ||
+
Michelle Don, MD, MS
 +
|3/19/2024
 +
|6/30/24
 +
|Pending
 +
| ||SK|| ||
 
|Hepatosplenic T-cell Lymphoma
 
|Hepatosplenic T-cell Lymphoma
 
|Michelle Don, MD, MS
 
|Michelle Don, MD, MS
Line 2,329: Line 2,384:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
−
| || || || ||SK|| ||
+
 
 +
Sumire Kitahara, MD
 +
| || ||Pending
 +
| ||SK|| ||
 
|Anaplastic Large Cell Lymphoma, ALK-Positive
 
|Anaplastic Large Cell Lymphoma, ALK-Positive
 
|Miguel Gonzalez Mancera, MD
 
|Miguel Gonzalez Mancera, MD
Line 2,341: Line 2,399:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee)
−
| || || || ||SK|| ||
+
Sumire Kitahara, MD
 +
| || ||Pending
 +
| ||SK|| ||
 
|Anaplastic Large Cell Lymphoma, ALK-Negative
 
|Anaplastic Large Cell Lymphoma, ALK-Negative
 
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
 
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
Line 2,349: Line 2,409:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
−
| || || || ||SK|| ||
+
|4/1/2024
 +
| ||Pending|| ||SK|| ||
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
 
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
Line 2,357: Line 2,418:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Issue - Rachel Burnside was working on this. Note says: "has prior content and name will change in 5th edition - Rachel working on this outside of production site to be replaced later by Nodal TFH Cell Lymphoma, Angioimmunoblastic-Type)". Where is her content as previous author names on 5th edition page||7/28/2023
+
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
−
| ||Pending|| ||SK|| ||
+
| ||Pending|| ||SK|| ||prior authors not available
 
|Angioimmunoblastic T-cell Lymphoma
 
|Angioimmunoblastic T-cell Lymphoma
 
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
 
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
Line 2,365: Line 2,426:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside||7/28/2023
+
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
 
| ||Pending|| ||SK|| ||
 
| ||Pending|| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,373: Line 2,434:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||PENDING
+
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
 
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
Line 2,381: Line 2,442:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
 +
|6/25/2023
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,388: Line 2,451:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,395: Line 2,458:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc
 +
|3/19/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,416: Line 2,482:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
 +
|3/25/2024
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,423: Line 2,491:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||PENDING
+
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
−
| || || || ||SK|| ||
+
|3/25/2024
 +
| || || ||SK|| ||prior authors not available
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/14048...14409"